01/07/2022 Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis
The Ministry of Health’s Drug Advisory Committee has recommended:
- Baricitinib 2 mg and 4 mg tablets...
01/07/2022 Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis
The Ministry of Health’s Drug Advisory Committee has recommended:
- Baricitinib 2 mg and 4 mg tablets for treating adults with moderately to severely active rheumatoid arthritis;
- Tofacitinib 5 mg tablet for treating adults with moderately to severely active rheumatoid arthritis; and
- Rituximab biosimilar (Truxima) 500 mg concentrate for infusion for treating adults with severely active rheumatoid arthritis
in line with their registered indications.
Subsidy status
RBaricitinib 2 mg and 4 mg tablets and tofacitinib 5 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.
RBaricitinib and tofacitinib should be used in line with the clinical criteria in the MAF checklist for initial and continuing prescriptions for patients with rheumatoid arthritis.
RRituximab biosimilar (Truxima) 500 mg concentrate for infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.
NRSDL subsidy and MAF assistance does not apply to any formulations or strengths of tocilizumab, rituximab reference biologic (MabThera) or other rituximab biosimilars (such as Rixathon).
18/01/2021 Rituximab for treating non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia
The Ministry of Health’s Drug Advisory Committee has recommended:
- Rituximab biosimilar (Truxima) 1...
18/01/2021 Rituximab for treating non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia
The Ministry of Health’s Drug Advisory Committee has recommended:
- Rituximab biosimilar (Truxima) 100 mg/10 ml and 500 mg/50 ml concentrate for infusion for treating:
- CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma,
- Indolent B-cell non-Hodgkin’s lymphomas,
- Stage III-IV follicular lymphoma, or
- CD20-positive chronic lymphocytic leukaemia
in line with its registered indications; and
- The removal of rituximab reference biologic 100 mg/10 ml and 500 mg/50 ml concentrate for infusion (MabThera) from the Medication Assistance Fund (MAF) for all indications.
Subsidy status
RTruxima 100 mg/10 ml and 500 mg/50 ml concentrate for infusion is recommended for inclusion in the MOH Standard Drug List (SDL) for the abovementioned indications from 18 January 2021. The MAF listing of MabThera will cease on 19 July 2021.
NRSDL subsidy does not apply to any other rituximab biosimilars (such as Rixathon), or to any formulations or strengths of MabThera.